Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
Launched by MICROBIO CO LTD · Jul 28, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new test called the Microbio InfectID-BSI kit, which aims to quickly detect bacteria and yeast in the blood of patients who might have serious infections like bloodstream infections or sepsis. The goal is to see how well this new test works compared to traditional methods that take longer, helping doctors identify infections more quickly and accurately.
To participate in the trial, individuals must be admitted to the hospital's Intensive Care Unit, Emergency Department, or other medical wards with a suspicion of a bloodstream infection. This includes babies, children, and adults who are at least one month old. Participants will have a blood sample taken, which will be tested using the Microbio kit. It’s important to note that only one blood sample per patient can be used, and it must be collected and stored correctly. If you or a loved one is interested in this trial, it could offer a chance to contribute to important research that may improve future diagnosis and treatment of infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female of neonates (less than 1 month of age), paediatrics (between 1 month and 17 years of age) or adults (\>18 years of age).
- • Admitted to ICU, Emergency Department, or other medical wards for acute illness with medical decision to perform blood culture for suspicion of bloodstream Infection.
- • Single EDTA blood sample collected from one anatomical site.
- • EDTA blood sample is stored according to Microbio's stability requirements.
- • EDTA blood volume is \>1mL.
- Exclusion Criteria:
- • No suspicion of Blood System Infection.
- • Any Inclusion Criterion not met.
- • Multiple EDTA blood samples from the same patient.
- • EDTA blood samples that have not been stored according to Microbio's stability requirements.
- • EDTA blood volume \<1mL.
About Microbio Co Ltd
Microbio Co., Ltd. is a pioneering biotechnology company dedicated to advancing microbiome research and development for innovative therapeutic solutions. With a commitment to harnessing the power of microbial ecosystems, Microbio focuses on creating targeted interventions aimed at improving health outcomes across various conditions. The company is engaged in cutting-edge clinical trials that explore the role of microbiota in disease management, striving to contribute to the future of personalized medicine. Through collaboration with leading research institutions and a team of experienced professionals, Microbio Co., Ltd. aims to transform scientific discoveries into practical applications that enhance patient care and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Houston, Texas, United States
Indianapolis, Indiana, United States
Woolloongabba, Queensland, Australia
Albuquerque, New Mexico, United States
Chermside, Queensland, Australia
Nashville, Tennessee, United States
Bristol, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported